News & Updates

Show Multimedia Only

Is pembrolizumab plus RT safe to administer in TNBC?

03 Mar 2026

Combination treatment with pembrolizumab and adjuvant radiotherapy (RT) does not pose any serious risk to patients with triple-negative breast cancer (TNBC), showing no increase in radiation-related adverse events (AEs), a study has shown.

Is pembrolizumab plus RT safe to administer in TNBC?

03 Mar 2026

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

03 Mar 2026 by

Treatment with sacituzumab tirumotecan (sac-TMT) shows a promising antitumour activity and an acceptable safety profile in patients with heavily pretreated advanced or metastatic urothelial carcinoma (UC), according to a phase II study.

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

03 Mar 2026

Tucatinib-T-DM1 combo improves PFS in patients with metastatic breast cancer

03 Mar 2026 by

Treatment with trastuzumab emtansine (T-DM1) plus tucatinib safely prolongs progression-free survival (PFS) in patients with previously treated HER2-positive locally advanced (LA) or metastatic breast cancer (MBC), including those with brain metastases, reports a study.

Tucatinib-T-DM1 combo improves PFS in patients with metastatic breast cancer

03 Mar 2026

Nirsevimab protects against LRTI-related hospitalizations, ED visits in young children

03 Mar 2026

Treatment with nirsevimab helps reduce hospitalizations and emergency department (ED) visits associated with lower respiratory tract infections (LRTIs) in infants and young children, according to the results of a meta-analysis.

Nirsevimab protects against LRTI-related hospitalizations, ED visits in young children

03 Mar 2026

Stopping antidepressants during pregnancy ups risk of mental health emergencies

02 Mar 2026 by

Most women on antidepressant therapy discontinue their medications during pregnancy despite guideline recommendations against doing so, and this practice results in more mental health emergencies, according to new research.

Stopping antidepressants during pregnancy ups risk of mental health emergencies

02 Mar 2026

Original New Drug Application Approvals by US FDA (1-15 February 2026)

02 Mar 2026

New drug applications approved by US FDA as of 1-15 February 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (1-15 February 2026)

02 Mar 2026

Does hormone therapy raise risk of IBD flare in gender-diverse adults?

02 Mar 2026

The risk of an inflammatory bowel disease (IBD) flare does not increase in the year after initiating gender-affirming hormone therapy (GAHT), but individuals with IBD prior to hormone start and those receiving testosterone have a higher likelihood of having an IBD flare, a study has shown.

Does hormone therapy raise risk of IBD flare in gender-diverse adults?

02 Mar 2026

Immune-related AEs linked to better outcomes in HCC patients

02 Mar 2026

Patients with hepatocellular carcinoma (HCC) who develop immune-related adverse events (irAEs) following treatment with an immune checkpoint inhibitor (ICI) tend to have more favourable clinical outcomes, including better progression free survival (PFS) and objective response rate (ORR), reports a recent study.

Immune-related AEs linked to better outcomes in HCC patients

02 Mar 2026

IV iron tied to higher risk of adverse perinatal outcomes in women with maternal IDA

02 Mar 2026 by

In a study presented at SMFM 2026, IV iron therapy is associated with a higher risk of certain adverse maternal and neonatal complications in women with iron deficiency anaemia (IDA) in pregnancy and postpartum.

IV iron tied to higher risk of adverse perinatal outcomes in women with maternal IDA

02 Mar 2026

New study favours prasugrel vs ticagrelor for patients with diabetes, multivessel disease

02 Mar 2026

In the treatment of patients with diabetes and multivessel disease undergoing percutaneous coronary intervention (PCI), clinical outcomes appear to be better with prasugrel than ticagrelor, according to the TUXEDO-2* study.

New study favours prasugrel vs ticagrelor for patients with diabetes, multivessel disease

02 Mar 2026

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Is pembrolizumab plus RT safe to administer in TNBC?

Is pembrolizumab plus RT safe to administer in TNBC?

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

Sacituzumab tirumotecan feasible in advanced urothelial carcinoma

Tucatinib-T-DM1 combo improves PFS in patients with metastatic breast cancer

Tucatinib-T-DM1 combo improves PFS in patients with metastatic breast cancer

Nirsevimab protects against LRTI-related hospitalizations, ED visits in young children

Nirsevimab protects against LRTI-related hospitalizations, ED visits in young children

Stopping antidepressants during pregnancy ups risk of mental health emergencies

Stopping antidepressants during pregnancy ups risk of mental health emergencies

Original New Drug Application Approvals by US FDA (1-15 February 2026)

Original New Drug Application Approvals by US FDA (1-15 February 2026)

Does hormone therapy raise risk of IBD flare in gender-diverse adults?

Does hormone therapy raise risk of IBD flare in gender-diverse adults?

Immune-related AEs linked to better outcomes in HCC patients

Immune-related AEs linked to better outcomes in HCC patients

IV iron tied to higher risk of adverse perinatal outcomes in women with maternal IDA

IV iron tied to higher risk of adverse perinatal outcomes in women with maternal IDA

New study favours prasugrel vs ticagrelor for patients with diabetes, multivessel disease

New study favours prasugrel vs ticagrelor for patients with diabetes, multivessel disease